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Abstract
SCFA resulting from the microbial fermentation of carbohydrates have been linked to increased glucagon-like peptide-1 (GLP-1) secretion
from the gastrointestinal tract in cell and animal models; however, there is little direct evidence in human subjects to confirm this. The
present study was designed to investigate whether endogenous plasma GLP-1 concentrations increase following acute consumption of
48 g dietary fibre (as resistant starch (RS) from high-amylose maize type 2 RS (HAM-RS2)) compared with a matched placebo. A total of
thirty healthy males participated in the present randomised cross-over study where HAM-RS2 or placebo was consumed as part of stan-
dardised breakfast and lunch meals. Changes to GLP-1, glucose, insulin and C-peptide were assessed half hourly for 7 h. Following the
breakfast meal, plasma GLP-1 concentrations were lower with HAM-RS2 compared with the placebo (P ¼ 0·025). However, there was
no significant difference between the supplements following the lunch meal. Plasma insulin concentrations were significantly lower fol-
lowing the lunch meal (P ¼ 0·034) with HAM-RS2 than with the placebo, but were not different after breakfast. Plasma glucose and C-pep-
tide concentrations did not differ at any point. These results suggest that increased dietary fibre intake, in the form of HAM-RS2, does not
acutely increase endogenous GLP-1 concentrations in human subjects. Further fibre feeding studies are required to determine whether
GLP-1 concentrations may increase following longer-term consumption.
Key words: Resistant starch: Dietary fibre: Glucagon-like peptide-1
Glucagon-like peptide-1 (GLP-1) is secreted from the endo-
crine L cells in the small and large intestine. GLP-17–36 (the
most biologically active form) is rapidly broken down by
protease enzymes, such as dipeptidyl peptidase-IV, to
GLP-19–36. GLP-1 has been well characterised as having two
main roles as a satiety hormone and as an incretin. As a satiety
hormone, GLP-1 has been shown to both enhance satiety and
reduce food intake, and has been proposed to be useful as a
treatment for weight management. The role of GLP-1 as an
incretin has been well defined, and it is believed that the
action of incretins may account for at least 50 % of insulin
that is released in response to oral glucose(1). As a result,
analogues of GLP-17–36, which are resistant to dipeptidyl
peptidase-IV, are being used as a therapeutic treatment for
type 2 diabetes.
Dietary carbohydrates that pass through the small intestine
to the colon can be classified as dietary fibre; these can act
as a substrate for the gut microbiota, leading to the production
of SCFA. It is these bioactive SCFA that in turn have been
proposed to increase the production of GLP-1. This is
thought to be mediated through SCFA binding to G-protein-
coupled receptors (free fatty acid receptor 2/3; FFAR2/3) on
GLP-1-secreting L cells in the colon(2). Therefore, the products
of the fermentation of fibres may cause an increase in
endogenous GLP-1 concentrations and thus may potentiate
the effects of GLP-1 as an incretin as well as a satiety signal.
Resistant starch (RS), a non-viscous fermentable dietary
fibre, has been shown in many animal studies to increase
GLP-1 production(3–5). Studies in human subjects where
GLP-1 has been measured following increased RS feeding
are limited(6–8), with only one of these being an acute feeding
study(8), and these have predominately shown no effect of RS
on GLP-1 concentrations. However, the beneficial effects that
have been observed following increased RS consumption, ran-
ging from 24 h to 12 weeks, have been an improvement in
insulin sensitivity(6,7,9,10), insulin secretion(11), a reduction in
food intake(12) and increased satiety(13,14). The only potential
candidate that could fulfil all of these roles would be GLP-1.
Our group has previously demonstrated a significant
reduction in food intake following increased RS intakes
(from high-amylose maize type 2 RS (HAM-RS2))(12). The pre-
sent study therefore aimed to follow a similar protocol
but specifically measuring the endogenous secretion of
GLP-1 and postprandial insulin and glucose concentrations.
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The study aimed to determine whether the previously
observed reductions in food intake and changes to postpran-
dial insulin concentrations could be due to increases in
endogenous GLP-1 concentrations.
Experimental methods
Participants
A total of thirty healthy adult males, with a mean age of 24·5
(SEM 0·7) years and a mean BMI of 26·2 (SEM 0·9) kg/m2, par-
ticipated in the present study. Participants were excluded if
they had a history of gastrointestinal or endocrine disease.
The present study was conducted according to the guidelines
laid down in the Declaration of Helsinki, and all procedures
involving human subjects were approved by the University
of Surrey Ethics Committee. Written informed consent was
obtained from all participants.
Study design
The study design was based on that described previously(12).
The study was a single-blind, cross-over study in which par-
ticipants visited the clinical unit on two occasions at least 1
week apart. On these clinical visits, participants consumed
either 80 g Hi-Maize 260w (comprising 60 % type 2 RS
(HAM-RS2) and 40 % rapidly digestible starch (RDS), therefore
providing 48 g HAM-RS2 as measured by the Association of
Official Analytical Chemists for total dietary fibre method
991.43) or 32 g of placebo (Amiocaw, comprising 100 % RDS)
supplying no dietary fibre. Both starches were manufactured
and supplied by Ingredion Inc. Half of the starch was pro-
vided at breakfast and the other half at lunch, incorporated
into a mousse, therefore providing 24 g dietary fibre or 0 g
dietary fibre at each meal.
On arrival at the clinical unit, a cannula was placed into the
antecubital fossa and two fasted blood samples were taken. At
time zero, participants consumed the standardised breakfast
(1587 kJ, 9·6 g protein, 67·1 g carbohydrate, 8·0 g fat and 0·5 g
dietary fibre (24·5 g dietary fibre for the HAM-RS2 supplement)).
Following the breakfast, blood samples were taken every 30 min
for 3 h. Participants were then provided with the standardised
lunch (3888 kJ, 36·1 g protein, 112·1 g carbohydrate, 37·0 g fat
and 5·0 g dietary fibre (29·0 g dietary fibre for the HAM-RS2
supplement)). Further blood samples were collected for the
following 4 h. Bowel habit and symptom diaries were com-
pleted on the day of the study and the following day to assess
gastrointestinal tolerance of the starches.
Biochemistry
Whole blood was collected into fluoroxalate tubes for glucose
analysis, potassium EDTA tubes for insulin analysis and
potassium EDTA tubes with 200 kallikrein-inhibiting units
aprotinin per ml of blood for C-peptide and total GLP-1
concentrations. All samples were centrifuged for 10 min at
3000 rpm and plasma stored at 2208C until batch analysis.
Plasma glucose concentrations were measured enzymatically
using a commercially available kit for the ILab650 (Instrumen-
tation Laboratory) and inter-assay variation was ,2 %. Plasma
insulin and C-peptide concentrations were measured by RIA
using commercially available kits (Millipore) with inter-assay
variations of 18·2 and 17·7 %, respectively, and intra-assay vari-
ations of 9·2 and 9·5 %, respectively. Plasma total GLP-1 con-
centrations were measured by ELISA using a commercially
available kit (Millipore) with an inter-assay variation of
15·0 % and an intra-assay variation of 4·5 %.
A priori power calculation and statistics
The thirty participants in the present cross-over study
(a ¼ 0·05) would yield an 80 % probability of detecting a
540 pmol/l per 420 min change in postprandial GLP-1
response (AUC, based on a treatment SD of 1018). All post-
prandial time course data were analysed using repeated-
measures ANOVA. The incremental AUC (iAUC) was
calculated for each meal using the trapezoid method, and
then the iAUC was compared between the treatments using
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Fig. 1. Postprandial plasma glucagon-like peptide-1 (GLP-1) concentrations. Values are means for thirty participants following 48 g high-amylose maize type 2
resistant starch (X) or placebo (W) consumption; consumed in two equal portions, one at time zero and the other at 180 min, with their standard errors represented
by vertical bars. There was a significant treatment £ time interaction using repeated-measures ANOVA (P ¼ 0·020).
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paired t tests. All statistical analyses were carried out using
SPSS version 18 for Windows (SPSS, Inc.) with significance
assumed as P , 0·05. All results presented are means with
their standard errors.
Results
Both HAM-RS2 and placebo were well tolerated by the partici-
pants with a similar frequency of bowel movements recorded
and no adverse gastrointestinal effects reported on the day of
the study or the following day. Participants’ weight did not
differ between the two study days.
Glucagon-like peptide-1 concentrations
There was a significant treatment £ time interaction between
HAM-RS2 and placebo for postprandial GLP-1 concentrations
(P ¼ 0·020; Fig. 1).
The iAUC for each meal showed a significantly lower GLP-1
response with HAM-RS2 compared with placebo following
breakfast (P ¼ 0·025; Fig. 2(a)). However, following the
lunch meal, there were no differences between the starches
(Fig. 2(a)).
Postprandial metabolite concentrations
Over the whole 7 h postprandial period, there were no differ-
ences between HAM-RS2 and placebo for concentrations of
plasma glucose, insulin or C-peptide.
The iAUC for insulin following breakfast (0–180 min) were
not different between HAM-RS2 and placebo; however, after
lunch (180–300 min), there was a significantly lower response
following HAM-RS2 than with placebo (P ¼ 0·034; Fig. 2(c)).
There were no significant differences in iAUC between the
RS and placebo for glucose or C-peptide (Fig. 2(b) and (d),
respectively).
Discussion
To our knowledge, this is the first study that has investigated
the effects of increased HAM-RS2 intake on endogenous
GLP-1 concentrations when compared with a placebo matched
for both energy and glycaemic load, in human subjects. The
present study has shown that during the 3 h following a break-
fast meal containing HAM-RS2, there was a significant reduction
in GLP-1 concentrations compared with placebo. However,
after a further HAM-RS2-containing meal, there was no differ-
ence in GLP-1 concentrations between the supplements.
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Fig. 2. Incremental AUC (iAUC) at each meal for plasma (a) glucagon-like peptide-1 (GLP-1), (b) glucose, (c) insulin and (d) C-peptide. Values are means for
thirty participants following 48 g high-amylose maize type 2 resistant starch (HAM-RS2, ) or placebo ( ) consumption; consumed in two equal portions at
breakfast (time zero) and lunch (180 min), with their standard errors represented by vertical bars. * Mean value was significantly different for GLP-1 iAUC at time
0–180 min with HAM-RS2 compared with placebo (P ¼ 0·025) but not significantly different at time 180–300 min. † Mean value was significantly different for insu-
lin iAUC at time 180–300 min with HAM-RS2 compared with placebo (P ¼ 0·034) but not significantly different at time 0–180 min. Mean values were not
significantly different for glucose or C-peptide concentrations.
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In the present acute postprandial study, increased intakes of
48 g HAM-RS2, a non-viscous fermentable fibre, did not
increase plasma GLP-1 concentrations and, indeed, following
the breakfast meal, GLP-1 concentrations were significantly
lower with the RS than compared with the placebo. There is
little previous direct evidence for an effect of RS on GLP-1
in human subjects. A postprandial study comparing 27 g RS
(from raw potato starch) with a placebo (that was not matched
for glycaemic carbohydrate) also found lower GLP-1 with
the RS(8). In the present study, there was a significant
treatment £ time interaction, translating as the RS-containing
meal giving a lower acute GLP-1 response with higher
post-lunch levels, when compared with placebo (Fig. 1).
This may suggest that the increase in GLP-1 concentrations
was due to the fermentation of HAM-RS2, and investigating
the effects later on in the day or even the subsequent morning
may have produced significant differences in GLP-1 concen-
trations. However, one study in which 60 g HAM-RS2 was
consumed for 24 h before the investigation compared with
the same placebo found no effect of HAM-RS2 on GLP-1 con-
centrations(6). Another study looking at carry-over effects of
evening meals varying in indigestible carbohydrate content
found no effect of evening meals on fasting GLP-1 concen-
trations the following day, but did demonstrate a significantly
higher GLP-1 AUC (0–120 min) following one treatment
(barley kernels containing 20·2 g of total dietary fibre) com-
pared with the control product (3·9 g of total dietary
fibre)(15). Additionally, a study in which 30 g HAM-RS2 was
consumed daily for 4 weeks compared with a matched glycae-
mic carbohydrate placebo again found no effect of HAM-RS2
on GLP-1(7), although, unlike the present study, this was not
an acute response to the fibre. Overall, the data from the pre-
sent study and from the previous studies would suggest that
HAM-RS2 does not cause an increase in endogenous GLP-1,
particularly when HAM-RS2 is consumed acutely.
While the GLP-1 data in human subjects following increased
RS intake are limited, there is much animal work that has
shown consistent increases in GLP-1 blood concentration fol-
lowing higher levels of RS feeding(3–5) as well as increases in
proglucagon gene expression in the caecum and colon(3,4,16).
However, it is difficult to directly translate these findings as the
studies in rodents have not been acute (days rather than
hours), and therefore it may be that prolonged exposure to
HAM-RS2 in human subjects is required to affect GLP-1 con-
centrations. A previous study in human subjects has shown
an increase in GLP-1 concentrations following wheat fibre
intake, although a year of increased wheat fibre feeding was
required before the effect was observed(17).
Other acute studies using increased fibre feeding have
shown inconsistent results. A 2 h postprandial study feeding
a galactose and guar gum-mixed drink compared with a con-
trol drink found increased GLP-1 concentrations(18); another
6 h postprandial study comparing an inulin drink with high-
fructose maize syrup drinks found GLP-1 concentrations to
be higher with inulin at 30 min(19). However, other studies
where dietary fibres have been given acutely, as in the present
study, have found no effect on GLP-1 concentrations(20,21).
Overall, a recent review has concluded that the current
research on the effects of fibres on GLP-1 demonstrates that
fibres do not increase GLP-1 concentrations compared with
control; however, the authors have acknowledged that there
are few studies that have actually assessed the effects of
fibre on gut hormones directly(22).
Previously, we have shown that acute ingestion of HAM-RS2
reduced postprandial insulin concentrations(12), which we
have demonstrated again in the present study following the
second dose of HAM-RS2, but not following the first dose,
or over the whole 7 h period. In the present study, the
lower insulin response observed after the second dose was
found in conjunction with a higher GLP-1 concentration,
which is not in agreement with GLP-1 acting as an incretin
following fibre feeding. This would therefore suggest that
following increased RS intakes, GLP-1 is unlikely to have a
role as an incretin. In many experimental designs, RS has
replaced portions of digestible starch, or ratios of amylose:
amylopectin have been manipulated (changing glycaemic
index and/or glycaemic load), thus making comparisons pro-
blematic. A recent review of the literature related to RS and
glycaemia/insulinaemia highlighted this disparity(23). In our
previous work, we hypothesised that a reduced postprandial
insulin response often attributed to RS intake may be due to
increased hepatic insulin clearance(12); however, we found
no evidence to support this in the present study.
The limitations of the present study are that we only
measured total as opposed to active GLP-17–36 concentrations
and therefore the effects of GLP-1 as a satiety signal may be
masked. As recently reviewed, gut hormones may not act
independently, and it may be the additive effects of several
gut hormones that result in observed changes to satiety(22).
Indeed, it is established that the postprandial levels of GLP-1
attained during feeding would have minimal effects on
food intake(24,25), when considered in isolation. However,
GLP-19–36 may still have a role as an incretin, as some studies
have suggested that it may reduce glycaemia to a small degree
independently to any effects on insulin secretion(26,27). There-
fore, the relevance of measuring total GLP-1 concentrations
needs to be considered in an attempt to understand the
health benefits of dietary fibre intake.
Overall, it would appear from the present study and that of
the literature that GLP-1 is not a candidate signal for the
acutely reduced food intake and enhanced insulin sensitivity
previously attributed to HAM-RS2.
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